RCM
ABEO icon

RA Capital Management’s Abeona Therapeutics ABEO Stock Holding History

RA Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-45,714
Closed -$5.54M – 25
2016
Q4 		$5.54M Buy
+45,714
New +$7.16M 0.79% 17

Other funds holding ABEO

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return
CHP
Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

RA Capital Management's ABEO Position: Q1 2017 in Review

RA Capital Management sold out of Abeona Therapeutics (ABEO) in Q1 2017, closing a stake of 45,714 shares — an estimated $5.54M sold.

RA Capital Management first reported a position in ABEO in Q4 2016 and held it in 1 quarter. The position peaked at $5.54M in Q4 2016. 58 funds tracked by Wall St. Rank hold ABEO as of Q1 2017.

  • RA Capital Management reported no remaining Abeona Therapeutics position as of Q1 2017 after selling out during the quarter.
  • RA Capital Management sold 45,714 Abeona Therapeutics shares in Q1 2017, an estimated $5.54M.
  • RA Capital Management first reported a position in Abeona Therapeutics in Q4 2016 and held it in 1 quarter.
  • RA Capital Management's Abeona Therapeutics position peaked at $5.54M in Q4 2016.
  • 58 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2017.

Based on RA Capital Management's 13F filing for Q1 2017, filed 15 May 2017.